发布时间：2024-09-29

文章标题：课题组近期文章速览！

内容：

课题组近期文章速览

 

恭喜许朋、郝谦、吕懋鑫、戴露瑶、刘丹丹同学的文章被接受发表

 

1.Maoxin Lv, Shihao Shang, Kepu Liu, Yuliang Wang, Peng Xu, Hao Song, Jie Zhang, Zelong Sun, Yuhao Yan, Zheng Zhu, Hao Wu*, and Hao Li*. Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. Pharmaceutics. 2024; 16(8):1067. 

 

2.Dandan Liu, Lidan Chang, Xuyan Zhao, Luyao Dai, Hanxiao Cui, Peinan Liu, Zhen Zhai, Hao Wu*, Xiaobin Ma*, Huafeng Kang*. Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases. Clinical breast cancer, 24(4), e232–e243.e1. 

 

3. Luyao Dai, Wenyu Yan, Xueting Ren, Dandan Liu, Lidan Chang, Shuai Lin, Hao Wu*, Huafeng Kang*, Xiaobin Ma*. Construction and Validation of a Nomogram Predicting the Overall Survival Benefit of Unilateral Breast Cancer Patients Undergoing Contralateral Prophylactic Mastectomy. Clinical breast cancer, 24(4), 351–362. 

 

4. Dandan Liu, Lidan Chang, Qian Hao, Xueting Ren, Peinan Liu, Xingyu Liu, Yumeng Wei, Meng Wang, Hao Wu*, Huafeng Kang*, Shuai Lin*. Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?. Journal of cancer research and clinical oncology, 150(5), 285. 

 

5. Qian Hao, Luyao Dai, Lidan Chang, Dingli Song, Dandan Liu, Xiaobin Ma*, Hao Wu*, Huafeng Kang*. Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer. Scientific reports, 14(1), 18055. 

 

6.Peng Xu, Wen Luo, Jingjing Hu, Xiaobin Ma, Qian Hao, Wentao Hui, Zhangjian Zhou, Shuai Lin, Meng Wang, Hao Wu*, Zhijun Dai*, Huafeng Kang*. Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients—A NCDB analysis (2010–2016). Cancer Med. 2024; 13:e7244.